Description: Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
Home Page: ascendispharma.com
ASND Technical Analysis
Tuborg Boulevard 12
Hellerup,
2900
Denmark
Phone:
45 70 22 22 44
Officers
| Name | Title |
|---|---|
| Mr. Jan Moller Mikkelsen | Pres, CEO, Member of Exec. Board & Exec. Director |
| Mr. Michael Wolff Jensen L.L.M. | Sr. VP, Chief Legal Officer & Member of the Exec. Board |
| Dr. Birgitte Volck M.D., Ph.D. | Sr. VP and Head of Clinical Devel. & Endocrinology Rare Diseases Medical Affairs |
| Mr. Scott T. Smith | CFO, Sr. VP & Member of Exec. Board |
| Ms. Lotte Sonderbjerg | Chief Admin. Officer, Sr. VP & Member of the Exec. Board |
| Mr. Peter Rasmussen | VP of Fin. & Principal Accounting Officer |
| Mr. Timothy J. Lee | Sr. Director of Investor Relations |
| Mr. Flemming Steen Jensen | Sr. VP of Product Supply & Quality |
| Dr. Kennett Sprogoe | Sr. VP and Head of Innovation & Research |
| Dr. Jens Sigurd Okkels Ph.D. | Sr. VP of Product Devel. |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 14.5547 |
| Price-to-Sales TTM: | 202.5734 |
| IPO Date: | 2015-01-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 639 |